NV-VELODYNE-LIDAR,-INC.
4.1.2019 20:02:08 CET | Business Wire | Press release
In advance of CES, Velodyne Lidar, Inc. today introduced trailblazing technology that will serve as the cornerstone of future advanced driving safety systems. The new products strengthen Velodyne’s position as the industry leader in providing the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005457/en/
Velodyne unveiled the VelaDome™, a compact embeddable lidar that provides an ultra-wide 180° x 180° image for near-object avoidance. Velodyne also introduced Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor as an integral component for advanced driver assistance systems (ADAS).
“With these new products, Velodyne’s robust solution portfolio meets the entire range of lidar needs for autonomy and driver assistance,” said Anand Gopalan, Ph.D., Chief Technology Officer (CTO) at Velodyne Lidar. “David Hall first deployed vehicle software in 2004 as part of the DARPA Challenges. Over the last 15 years, Velodyne has continued to add intelligence to our sensors, enabling a variety of lidar sensing capabilities that allow our customers to detect more objects and offer cars a more detailed view of their surroundings. Now we will take it even further and our new software, which was developed in close collaboration with our lidar hardware experts, will enable a seamlessly integrated ADAS solution powered by our lidars.”
The Lidar Assistant (Vella): Software that Revolutionizes ADAS Performance
Velodyne presented a groundbreaking advanced driver assistance solution that builds upon its directional view Velarray sensor. Vastly superior to existing approaches that utilize camera+radar, this solution will revolutionize advanced driver assistance functionalities currently on the market, such as Lane Keeping Assist (LKA), Automatic Emergency Braking (AEB), and Adaptive Cruise Control (ACC).
VelaDome: Close-Range Precision
The VelaDome’s game-changing hemispherical field of view and high-density image present a quantum leap in pedestrian, cyclist, and blind-spot detection. The compact sensor is ideal for a variety of mounting and styling options. Powered by Velodyne’s patented Micro Lidar Array (MLA) technology, the VelaDome is optimized for manufacturability and designed to meet automotive-grade standards. Like all Velodyne sensors, VelaDome has world-class technical support available across North America, Europe, and Asia.
For more information on Velodyne and to download news releases, photos, and videos, please visit https://velodynelidar.com/newsroom/ . Media can schedule an executive interview or product demo by contacting Robin Carr at Landis Communications Inc. (415-971-3991; velodyne@landispr.com ).
About Velodyne Lidar
Velodyne provides the smartest, most powerful lidar solutions for autonomy and driver assistance. Founded in 1983 and headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. In 2005, Velodyne’s Founder and CEO, David Hall, invented real-time surround view lidar systems, revolutionizing perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the perfect for L4-L5 autonomy Alpha Puck™, the ultra-wide angle VelaDome™, and the ADAS-optimized Velarray™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005457/en/
Contact:
Robin Carr Landis Communications Inc. (415) 971-3991 velodyne@landispr.com www.landispr.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom